Multiple Myeloma

Before closing out their discussion on multiple myeloma management, panelists reflect on real-world clinical practice perspectives on treatment with bispecifics.

Experts from the Mayo Clinic and Moffitt Cancer Center go head-to-head to discuss recent data in multiple myeloma and updates from recent meetings.

An expert from Stanford Medicine that the goal behind a study characterizing circulating tumor DNA and its predictive value is to eventually replace blood marrow exams with a blood draw for those with multiple myeloma.

Rahul Banerjee, MD, FACP, discusses a recent presentation from the Tandem meeting regarding BCMA CAR T-cell therapy in patients with multiple myeloma.

Evidence from a matched pair comparison with a concurrent control cohort suggests that panobinostat plus gemcitabine, busulfan, and melphalan improves progression-free survival in those with relapsed or refractory multiple myeloma, especially after first transplant.

A brief review of talquetamab, a novel agent in the setting of relapsed/refractory multiple myeloma that targets GPRC5D.

Following their discussion on teclistamab, experts from the Moffit Cancer Center highlight other BCMA-targeted therapies available in the relapsed/refractory setting of multiple myeloma.

The FDA and European Medicines Agency accept applications for elranatamab for relapsed or refractory multiple myeloma.

Anne-Marie Jacob shares advice for patients with multiple myeloma receiving teclistamab who are recommended for hospital admission for CRS risk.

Nurse Practitioner Kiah Purcell explains how she discusses supportive care agents with patients receiving a BCMA-targeting bispecific for multiple myeloma in case a patient experiences cytokine release syndrome.

Expert panelists discuss treatment approaches for patient with multiple myeloma that have progressed and are relapsed and/or refractory (R/R).

Experts offer final thoughts on the treatment of newly diagnosed MM for patients that are transplant-ineligible.

Expert perspectives on the advent of CAR T-cell therapy in relapsed/refractory multiple myeloma, and how its role may integrate with bispecific antibody therapy.

Before closing out their discussion on bispecific antibodies in relapsed/refractory multiple myeloma, key opinion leaders consider optimal sequencing of these agents.

A review of novel treatment modalities for relapsed/refractory multiple myeloma, with a focus on selecting and sequencing bispecific antibodies and CAR T-cell therapies.

Expert panelists center discussion on a final patient case to review the identification and management of relapsed/refractory multiple myeloma.

Sikander Ailawadhi, MD, discussed the safety and efficacy of talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma following a readout of the phase 1/2 MonumenTAL-1 trial.

Panelists review data from the MajesTEC-1 clinical trial and elucidate the role of teclistamab therapy in patients with relapsed/refractory multiple myeloma.

Shared insight on the value of using effective regimens upfront and optimal sequencing throughout several lines of therapy in multiple myeloma.

The investigational CAR T-cell therapy equecabtagene autoleucel receives fast track and regenerative medicine advanced therapy designations for managing relapsed or refractory multiple myeloma.

A review of the process of “step-up” doses in teclistamab therapy for multiple myeloma and their use.

A review of the process of giving a patient a dose of teclistamab from start to finish.

Survival appears to be significantly improved when idecabtagene vicleucel is given vs standard of care in relapsed/refractory multiple myeloma.

Oncology expert panelists review patient subgroup analyses for MAIA and SWOG0777 studies, investigating treatments for transplant-ineligible patients with newly diagnosed multiple myeloma.

Expert panelists review clinical data from studies investigating treatment regimens for patients with NDMM that are transplant-ineligible.